ReviewFrontiers in immunology2020
NK Cell-Based Immune Checkpoint Inhibition.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 265 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
265 citing papers in PubMed, 346 citations in OpenAlex.
- First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies.Cancer research communications · 2025Trial
- Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.Nature medicine · 2022Trial
- TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.Nature cancer · 2026Article
- Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer.Cancer research · 2026Article
- Immune cells in liver transplantation: Dual roles, mechanistic insights, and targeted therapeutic strategies.Immunologic research · 2026Review
- Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer.Journal of translational medicine · 2026Article
- Precision Fc remodeling via glycosylation-competent CHO display enables ultra-selective FcγRIIIa targeting and enhanced antitumor activity.Journal of biological engineering · 2026Article
- Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2026Article
- HO-1-driven drug resistance in hematological malignancies: Mechanistic insights and advances in targeted therapy.iScience · 2026Review
- CRISPR/Cas9-mediated B2m knockout paves the way for allogeneic basal cell transplantation.Respiratory research · 2026Article
- Discovery and preclinical evaluation of monoclonal antibodies and bispecific engagers targeting the NKG2A inhibitory receptor.Science advances · 2026Article
- Subgroup-specific predictive biomarkers in peripheral blood lymphocyte subsets for immune checkpoint inhibitor response in advanced esophageal squamous cell carcinoma: a prospective study.Journal of thoracic disease · 2026Article
- Cell therapy in sarcoma: current landscape and future directions.Journal for immunotherapy of cancer · 2026Review
- CD244 overexpression indicates NK cell dysfunction and tumor progression in diffuse large B-cell lymphoma.Frontiers in immunology · 2026Article
- The spatial revolution in immuno-oncology: artificial intelligence decoding NK cell niches to predict therapeutic response.Frontiers in immunology · 2026Review
- Natural killer cells at the interface of tumor immune escape and immunotherapy resistance in endometrial cancer.Frontiers in immunology · 2026Review
- The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity.Antibody therapeutics · 2026Article
- The immune microenvironment of HPV-associated cancers: from viral oncogenesis to immunotherapy response.Frontiers in immunology · 2026Review
205 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy, with an increasing number of therapeutic dimensions, is becoming an important mode of treatment for cancer patients. The inhibition of immune checkpoints, which are the source of immune escape for various cancers, is one such immunotherapeutic dimension. It has mainly been aimed at T cells in the past, but NK cells are a newly emerging target. Simultaneously, the number of checkpoints identified has been increasing in recent times. In addition to the classical NK cell receptors KIRs, LIRs, and NKG2A, several other immune checkpoints have also been shown to cause dysfunction of NK cells in various cancers and chronic infections. These checkpoints include the revolutionized CTLA-4, PD-1, and recently identified B7-H3, as well as LAG-3, TIGIT & CD96, TIM-3, and the most recently acknowledged checkpoint-members of the Siglecs family (Siglec-7/9), CD200 and CD47. An interesting dimension of immune checkpoints is their candidacy for dual-checkpoint inhibition, resulting in therapeutic synergism. Furthermore, the combination of immune checkpoint inhibition with other NK cell cytotoxicity restoration strategies could also strengthen its efficacy as an antitumor therapy. Here, we have undertaken a comprehensive review of the literature to date regarding NK cell-based immune checkpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.